Are you Dr. Butrynski?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 105 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
520 Country Club Pkwy
Eugene, OR 97401Phone+1 541-683-5001Fax+1 541-683-1422
Summary
- Dr. James Butrynski, MD is an oncologist in Eugene, Oregon. He is currently licensed to practice medicine in Oregon, Massachusetts, and Washington. He is affiliated with PeaceHealth Sacred Heart Medical Center at RiverBend and is an Instructor in Medicine at Dana-Farber Cancer Institute.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1998 - 1998
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1996 - 1998
Massachusetts General HospitalResidency, Internal Medicine, 1993 - 1996
Wayne State University School of MedicineClass of 1993
Certifications & Licensure
OR State Medical License 2017 - 2025
WA State Medical License 1998 - 2017
MA State Medical License 2007 - 2015
MD State Medical License 1996 - 1998- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer Start of enrollment: 2000 Jul 01
- Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2011 May 01
- Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas Start of enrollment: 2012 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsEfficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer.Alessandro D Santin, Bradley R Corr, Alexander Spira, Lyndsay Willmott, James Butrynski
Journal of Clinical Oncology. 2024-10-10 - 19 citationsResults of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung.Kristin Baird, John Glod, Seth M. Steinberg, Denise K. Reinke, Joseph G. Pressey
Sarcoma. 2020-04-30 - 74 citationsLong-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard...Eytan Ben-Ami, Constance M. Barysauskas, M. von Mehren, Michael Heinrich, Christopher L. Corless
Annals of Oncology. 2016-09-01
Grant Support
- Novel Radioimmunotherapy For LymphomaNational Cancer Institute2000–2001
Professional Memberships
- Member
